Understanding the clinical care pathway of patients with mild cognitive impairment due to Alzheimer's disease and dementia due to Alzheimer's disease: Results from a global real‐world survey
Our results highlight a lack of awareness of early symptoms, inconsistent referral, and infrequent utilization of AD specific biomarkers. Addressing these challenges is pivotal to facilitate early, accurate diagnosis and intervention. Lack of efficacy was the main reason for changing initial treatment, indicating the need for better treatment options.
Authors
- Hisatomo Kowa (ORCID: https://orcid.org/0000-0002-5300-8589)
- Sarah Cotton (ORCID: https://orcid.org/0000-0003-1158-6345)
- Chloe J. Walker (ORCID: https://orcid.org/0000-0002-6841-5806)
- Juan M. Fortea (ORCID: https://orcid.org/0000-0002-1340-638X)
- Nachiappan KR
- Sharon Cohen
- Luis R Solís Tarazona
Institutions
- Hyogo University of Health Sciences (JP)
- Novo Nordisk (Denmark) (DK)
- Hospital de Sant Pau (ES)
- Adelphi Group (United Kingdom) (GB)
- Novo Nordisk (India) (IN)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70858_100805
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00